Results 101 to 110 of about 25,544 (130)
Unlocking Longevity in Aesthetic Dermatology: Epigenetics, Aging, and Personalized Care
International Journal of Dermatology, EarlyView.Unlocking longevity in aesthetic dermatology: epigenetics, aging, and personalized care. ABSTRACT The concept of aging has evolved from being primarily attributed to genetic factors to recognizing the critical role of epigenetic mechanisms. Recent advancements, such as epigenetic clocks, have provided tools to assess biological age and offer insights ...
Diala Haykal +4 more
wiley +1 more source
Identification of Target Genes Using Innovative Screening Systems
Pathology International, EarlyView.ABSTRACT Advances in cancer biology have been achieved by the identification of oncogenes and tumor suppressor genes through the remarkable progression of next‐generation sequencing. New techniques, such as single‐cell analysis, help uncover cancer progression and heterogeneity.
Keisuke Sugita, Morito Kurata
wiley +1 more source
Veterinary and Comparative Oncology, EarlyView.ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is one of the most prevalent haematological malignancies in both humans and dogs, characterised in both species by significant clinical heterogeneity and limited prognostic predictability. With the introduction of next‐generation sequencing (NGS) technologies in veterinary medicine over the past decade ...
Antonella Fanelli +4 more
wiley +1 more source
Veterinary Clinical Pathology, EarlyView.Abstract Acute myeloid leukemia (AML) poses significant challenges in veterinary medicine, with limited treatment options and poor survival rates. While substantial progress has been made in characterizing human AML, translating these advancements to veterinary practice has been hindered by limited molecular understanding and diagnostic tools. The case
R. Adam Harris +5 more
wiley +1 more source
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
CA: A Cancer Journal for Clinicians, EarlyView.Abstract The peripheral T‐cell lymphomas (PTCL) are the only disease for which four histone deacetylase (HDAC) inhibitors have been approved globally as single agents. Although it is not clear why the PTCL exhibit such a vulnerability to these drugs, understanding the biological basis for this activity is essential.
Ariana Sabzevari +7 more
wiley +1 more source
Unveiling roles of non‐coding RNAs in cancer through advanced technologies
Quantitative Biology, Volume 13, Issue 4, December 2025.Abstract Non‐coding RNAs (ncRNAs) have emerged as key regulators in tumorigenesis. In this perspective, we briefly review the significance of ncRNA in cancer biology and highlight recent technological advancements in characterization of ncRNA in cancer research. Specifically, we discuss how these advanced approaches, such as Patho‐DBiT, CRISPR screens,
Runhao Wang, Leng Han
wiley +1 more source
International Journal of Cancer, Volume 157, Issue 2, Page 371-383, 15 July 2025.What's new? While estrogens, obesity, and alcohol are recognized risk factors for breast cancer, a viral hypothesis has been suggested based on the murine model of Mouse Mammary Tumor Virus (MMTV)‐induced mammary tumors. This study analyzed sequences of the human homolog of MMTV across human breast carcinoma histotypes, detecting the virus in all types
Prospero Civita +12 more
wiley +1 more source
Histopathology, Volume 87, Issue 1, Page 110-129, July 2025.Here we report the features of 24 BAP1‐inactivated melanocytic tumours including 19 BAP1‐inactivated melanocytomas (BIMs) and five BAP1‐inactivated melanomas. BIMs have a favourable prognosis, even those with multiple copy number aberrations (CNAs).
Joseph S. Durgin +9 more
wiley +1 more source
Advanced Science, Volume 12, Issue 21, June 5, 2025.Lysine demethylase 6A (KDM6A), an epigenetic regulator expressed in hematopoietic stem and progenitor cells (HSPCs), plays a critical role in hematopoietic homeostasis. Deficiency of KDM6A induces myeloid lineage skewing and drives the development of a chronic myelomonocytic leukemia (CMML)‐like disease.
Huiqiao Chen +11 more
wiley +1 more source
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, Volume 100, Issue S4, Page 88-115, June 2025.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53 mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source